The Irish Anticoagulation Forum hosted workshops to highlight safety issues surrounding various anticoagulants, including Xarelto (generic name rivaroxaban). Presenters focused on avoiding negative drug interactions between Xarelto and common drugs like aspirin — a combination that led some patients to renal impairment and poor hemoglobin levels.
Blood thinners like Xarelto have been used heavily in post-surgery patients and other patients suffering from particular conditions in order to reduce the risk of blood clots and stroke. Unfortunately, Xarelto does not contain a natural antidote to reverse its blood thinning effects, which leaves patients susceptible to severe side effects such as internal hemorrhaging.
Thousands of patients have reported adverse Xarelto events after being give the anticoagulant, including strokes, heart attacks and internal bleeding. More than 890 people have been hospitalized due to Xarelto complications, and more than 180 deaths have been associated with Xarelto.